Nonalcoholic fatty liver disease following liver transplantation

Sanjaya Satapathy, Satheesh Nair, Jason M. Vanatta

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Post-transplant, nonalcoholic hepatic steatosis and steatohepatitis are increasingly recognized as a complication of liver transplantation, and the progression of the latter through fibrosis to cirrhosis has been clearly shown. Non-alcoholic steatohepatitis (NASH) is independently associated with an increased risk of death from cardiovascular and liver diseases. While optimal therapy is not yet available in the post-liver transplant setting, knowledge gained in the therapy of NASH in the non-transplant setting can be used to design therapeutic interventions. In addition, early recognition with protocol liver biopsies and an effective preventive strategy by modifying known risk factors implicated in the recurrence of NASH would be the most effective way to curtail the progression of NASH before an effective treatment can be found. Additional rigorous research aimed at elucidating the pathogenesis, natural history, and selection of immunosuppressants for NASH is clearly warranted.

Original languageEnglish (US)
Pages (from-to)400-412
Number of pages13
JournalHepatology International
Volume7
Issue number2
DOIs
StatePublished - Jun 1 2013

Fingerprint

Fatty Liver
Liver Transplantation
Liver
Fibrosis
Transplants
Genetic Selection
Therapeutics
Immunosuppressive Agents
Natural History
Non-alcoholic Fatty Liver Disease
Liver Diseases
Cardiovascular Diseases
Biopsy
Recurrence
Research

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Nonalcoholic fatty liver disease following liver transplantation. / Satapathy, Sanjaya; Nair, Satheesh; Vanatta, Jason M.

In: Hepatology International, Vol. 7, No. 2, 01.06.2013, p. 400-412.

Research output: Contribution to journalReview article

Satapathy, Sanjaya ; Nair, Satheesh ; Vanatta, Jason M. / Nonalcoholic fatty liver disease following liver transplantation. In: Hepatology International. 2013 ; Vol. 7, No. 2. pp. 400-412.
@article{5858a52206404bb695566449e3867603,
title = "Nonalcoholic fatty liver disease following liver transplantation",
abstract = "Post-transplant, nonalcoholic hepatic steatosis and steatohepatitis are increasingly recognized as a complication of liver transplantation, and the progression of the latter through fibrosis to cirrhosis has been clearly shown. Non-alcoholic steatohepatitis (NASH) is independently associated with an increased risk of death from cardiovascular and liver diseases. While optimal therapy is not yet available in the post-liver transplant setting, knowledge gained in the therapy of NASH in the non-transplant setting can be used to design therapeutic interventions. In addition, early recognition with protocol liver biopsies and an effective preventive strategy by modifying known risk factors implicated in the recurrence of NASH would be the most effective way to curtail the progression of NASH before an effective treatment can be found. Additional rigorous research aimed at elucidating the pathogenesis, natural history, and selection of immunosuppressants for NASH is clearly warranted.",
author = "Sanjaya Satapathy and Satheesh Nair and Vanatta, {Jason M.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s12072-013-9434-3",
language = "English (US)",
volume = "7",
pages = "400--412",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease following liver transplantation

AU - Satapathy, Sanjaya

AU - Nair, Satheesh

AU - Vanatta, Jason M.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Post-transplant, nonalcoholic hepatic steatosis and steatohepatitis are increasingly recognized as a complication of liver transplantation, and the progression of the latter through fibrosis to cirrhosis has been clearly shown. Non-alcoholic steatohepatitis (NASH) is independently associated with an increased risk of death from cardiovascular and liver diseases. While optimal therapy is not yet available in the post-liver transplant setting, knowledge gained in the therapy of NASH in the non-transplant setting can be used to design therapeutic interventions. In addition, early recognition with protocol liver biopsies and an effective preventive strategy by modifying known risk factors implicated in the recurrence of NASH would be the most effective way to curtail the progression of NASH before an effective treatment can be found. Additional rigorous research aimed at elucidating the pathogenesis, natural history, and selection of immunosuppressants for NASH is clearly warranted.

AB - Post-transplant, nonalcoholic hepatic steatosis and steatohepatitis are increasingly recognized as a complication of liver transplantation, and the progression of the latter through fibrosis to cirrhosis has been clearly shown. Non-alcoholic steatohepatitis (NASH) is independently associated with an increased risk of death from cardiovascular and liver diseases. While optimal therapy is not yet available in the post-liver transplant setting, knowledge gained in the therapy of NASH in the non-transplant setting can be used to design therapeutic interventions. In addition, early recognition with protocol liver biopsies and an effective preventive strategy by modifying known risk factors implicated in the recurrence of NASH would be the most effective way to curtail the progression of NASH before an effective treatment can be found. Additional rigorous research aimed at elucidating the pathogenesis, natural history, and selection of immunosuppressants for NASH is clearly warranted.

UR - http://www.scopus.com/inward/record.url?scp=84876456720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876456720&partnerID=8YFLogxK

U2 - 10.1007/s12072-013-9434-3

DO - 10.1007/s12072-013-9434-3

M3 - Review article

AN - SCOPUS:84876456720

VL - 7

SP - 400

EP - 412

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 2

ER -